Skip to main content
TipRanks
Go Ultimate75% OFF

Pro-Dex (PDEX) AI Stock Analysis

111 Followers
PDEX

Pro-Dex

(NASDAQ:PDEX)

Select Model
Rating:68Neutral
Price Target:$72.00â–²(16.26% Upside)
Action:downgraded
Date:10/31/26

The score is primarily supported by materially improved financial performance (strong TTM profitability, ROE, and improving leverage). This is tempered by weak near-term technicals (below key moving averages with negative MACD and low RSI) and only moderately positive corporate developments, while valuation appears reasonable based on the current P/E and no dividend yield support.

Positive Factors
Profitability and Revenue GrowthPro-Dex has materially strengthened its earnings profile while scaling revenue, demonstrating improved operating execution and meaningful current profitability. If these levels remain durable, the company can fund investment, reinforce its specialized medical-device position, and convert growth into stronger long-term earnings power.
Negative Factors
Historically Volatile Cash ConversionAlthough current cash generation is positive, the history of negative operating and free cash flow shows that reported earnings do not always translate consistently into cash. Working-capital timing may therefore create uneven funding capacity and make financial performance less resilient during weaker operating periods.

Pro-Dex Key Performance Indicators (KPIs)

Revenue by SegmentHighlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.

$0.00$5.00M$10.00M$15.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Pro-Dex’s growth has become increasingly concentrated in Orthopedic, which has established a much higher run rate since late 2024 and continues to expand despite modest quarterly pullbacks. CMF remains a volatile but relatively stable secondary contributor, while Thoracic has lost much of its earlier scale and has not regained consistent momentum. This mix shift strengthens near-term growth but increases reliance on sustained orthopedic demand and customer programs.

Data provided by:The Fly

Pro-Dex (PDEX) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%PDEX+100.88%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$198.18M
Dividend Yield
―
Average Volume (3M)
54.31K
Price to Earnings (P/E)
16.6
Beta (1Y)
0.38
Revenue Growth
13.31%
EPS Growth
9.26%
Country
US
Employees
204
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Pro-Dex Business Overview & Revenue Model

Company Description

Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio fe...

How the Company Makes Money

Pro-Dex primarily makes money by providing contract manufacturing and engineering services to medical device original equipment manufacturers (OEMs). Revenue is generated through (1) manufacturing and assembly of powered surgical instruments and rela...

Pro-Dex Financial Statement Overview

Summary

Strong TTM profitability and scale-up (revenue ~$79.6M, ~32% gross margin, ~15% operating/net margins) with solid ROE (~26%) and improving leverage (debt-to-equity ~0.38). Offsetting this, cash flow has been historically volatile and cash conversion is not consistently >1x net income, indicating working-capital timing and some margin volatility risk.

Income Statement

84Very Positive

Balance Sheet

78Positive

Cash Flow

73Positive
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue79.58M77.55M66.59M53.84M46.09M42.04M
Gross Profit25.82M24.34M19.51M14.55M12.75M13.13M
EBITDA17.14M14.38M14.13M4.35M10.82M6.88M
Net Income12.03M13.66M8.98M2.13M7.07M4.57M
Balance Sheet
Total Assets76.59M74.51M61.19M52.48M51.82M49.09M
Cash, Cash Equivalents and Short-Term Investments12.99M9.34M7.16M6.85M4.07M1.60M
Total Debt18.98M18.10M16.58M13.55M14.79M15.97M
Total Liabilities27.24M26.88M24.56M21.61M20.23M23.66M
Stockholders Equity49.35M47.63M36.63M30.87M31.59M25.43M
Cash Flow
Free Cash Flow10.82M6.76M-2.93M5.22M4.49M-2.52M
Operating Cash Flow11.42M7.24M-1.68M6.20M5.46M-847.00K
Investing Cash Flow3.67M3.91M-238.00K-2.23M-885.00K-1.24M
Financing Cash Flow-10.52M-3.38M-292.00K-4.27M-2.49M-790.00K

Pro-Dex Technical Analysis

Technical Analysis SentimentNegative
Last Price61.93

Price Trends

50DMA64.77Negative
100DMA63.44Negative
200DMA58.01Positive

Market Momentum

MACD0.66Negative
RSI45.92Neutral
STOCH35.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDEX, the sentiment is Negative. The current price of 61.93 is below the 20-day moving average (MA) of 63.39, below the 50-day MA of 64.77, and above the 200-day MA of 58.01, indicating a neutral trend. The MACD of 0.66 indicates Negative momentum. The RSI at 45.92 is Neutral, neither overbought nor oversold. The STOCH value of 35.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PDEX.

Pro-Dex Risk Analysis

Pro-Dex disclosed 24 risk factors in its most recent earnings report. Pro-Dex reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our acquisition of APM may increase our exposure to complex export control and government contracting requirements, the violation of which could have a material adverse effect on our business.Q2, 2026
2.Other PDEX symbols exist in the marketplace, and the association may create confusion.Q3, 2025
3.Artificial intelligence ("AI") may be generating information that is used incorrectly and may lead to an adverse effect on our business.Q3, 2025

Pro-Dex Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PDEX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UTMDUTMD73Outperform$205.22M21.438.78%1.72%-9.62%-5.65%
PDEXPDEX68Neutral$198.18M16.5626.18%―13.31%9.26%
KRMDKRMD57Neutral$151.38M-195.480.00%―18.43%78.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%PDEXUTMDMBOTKRMDZJYLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PDEX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PDEXPro-dex61.9333.02114.22%
UTMDUtah Medical Products72.0219.1436.19%
MBOTMicrobot Medical0.69-1.23-64.11%
KRMDRepro-Med Systems, Inc.3.49-0.86-19.77%
ZJYLJin Medical International Ltd.3.38-1.87-35.69%

Pro-Dex Corporate Events

Business Operations and Strategy

Pro-Dex expands Costa Mesa industrial footprint with new lease

Positive
Oct 30, 2026

On October 26, 2026, Advanced Precision Machining renewed three leases for about 2,500 square feet of office and industrial space in Costa Mesa, extending their terms to September 30, 2030 and locking in base rent increases of 4.0% to 6.6% starting F...

Business Operations and Strategy

Pro-Dex Extends Irvine Headquarters Lease Through 2030

Positive
Sep 18, 2026

On September 16, 2026, Pro-Dex entered into a Third Amendment to its long-standing lease for its Irvine headquarters and manufacturing facility, effective August 18, 2026, extending the lease term to September 30, 2030. The amendment introduces 3.5%...

Executive/Board ChangesFinancial Disclosures

Pro-Dex Awards Executive Bonuses After Strong Fiscal 2026

Positive
Aug 28, 2026

On August 26, 2026, Pro-Dex’s compensation committee approved discretionary cash bonuses for Chief Executive Officer Richard L. Van Kirk and Chief Financial Officer Alisha K. Charlton, to be paid in the next bi-weekly pay period with a pay date of Se...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026